跳到正文
MarketHOT
English
摘要
SEC · EDGAR 财务披露·· 11 天前AI 评分19

Processa Pharmaceuticals 提交 8-K,披露致股东信

Processa Pharmaceuticals, Inc. (0001533743) (Filer)

AI 导读

Processa Pharmaceuticals 于 11 月 5 日提交 Form 8-K,披露公司当天向股东发出一封信,并将其作为附件 99.1 提交。文件标明相关材料属于《交易法》Rule 14a-12 下的征求材料;公司普通股代码为 PCSA,在纳斯达克交易。

正文

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 5, 2026

Processa Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-39531

45-1539785

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

601 21st Street, Suite 300

Vero Beach, FL 32960

(Address of principal executive offices, including zip code)

(772) 453-2899

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☒

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trade

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.0001 par value per share

 

PCSA

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 8.01

Other Events.

On November 5, 2026, Processa Pharmaceuticals, Inc. (the “Company”) issued a letter to the Company’s stockholders (the “Stockholder Letter”). A copy of the Stockholder Letter is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01

Financial Statements and Exhibits.

(d)          Exhibits.

Exhibit

Number

 

Description

   

99.1

 

Stockholder Letter, dated November 5, 2026.

   

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Processa Pharmaceuticals, Inc.

   

Date: November 5, 2026

By:

/s/ Russell Skibsted

 

Name:

Russell Skibsted

 

Title:

Chief Financial Officer


来源:SEC EDGAR · 本站存档